Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IM-19 by Beijing Immunochina Pharmaceuticals for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...
IM-19 by Beijing Immunochina Pharmaceuticals for Mantle Cell Lymphoma: Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Mantle Cell Lymphoma. According to...
IM-19 by Beijing Immunochina Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
IM-19 by Beijing Immunochina Pharmaceuticals for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
IM-19 by Beijing Immunochina Pharmaceuticals for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...
IM-19 by Beijing Immunochina Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval
IM-19 is under clinical development by Beijing Immunochina Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData,...